DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Elekta Unity MR-linac gains FDA 510(k) clearance Simultaneously delivers radiation dose and visualization of tumors

Dr. Hermann Requardt United Imaging Healthcare appoints senior scientific advisor

Patient denied proton therapy dies, family received $25 million in court Points to the need for greater treatment coverage for certain cancer patients

Microbeam radiation therapy could lead to single session treatments Healthy cells tolerate treatment while tumors lose structure

CMS to unveil mandatory payment model for radiation oncology Part of determining approach that saves more and offers greater quality

European report says radiotherapy 'undervalued' and needing 'greater investment' Equipment shortages, lack of investment, training variations

ViewRay to supply UK's GenesisCare with country's first MRIdian systems Providing soft-tissue imaging in real time and better tumor targeting

Accuray showcases software upgrades for CyberKnife and Radixact at ASTRO Allows for 40 percent faster treatment delivery

Precision cancer care with proton and radiation oncology Some of the latest systems and software entering the market

IBA Dosimetry debuts myQA Daily at ASTRO 2018 Has 125 ionization chamber measurement points

Radiotherapy does not benefit end-stage lung cancer patients

by John W. Mitchell , Senior Correspondent
A widespread protocol for end-stage, non-small cell lung cancer patients whose disease has metastasized into their brain does not improve survival according to just-published findings in the British medical journal The Lancet.

"Before the QUARTZ trail, there was no evidence that whole brain radiotherapy enhanced our non-small cell lung cancer patients' quality of life or overall survival," Dr. Paula Mulvenna, Consultant Clinical Oncologist, Newcastle Hospitals NHS Foundation Trust, U.K. told HCB News.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



The Quality of Life after Treatment for Brain Metastases (QUARTZ) trial included 538 patients from 69 health centers in the U.K. and three in Australia between March, 2007 and August, 2014. The patients were randomly assigned to two different protocol groups, with one group receiving radiotherapy as part of their care.

The data demonstrated that patients in both groups lived about 65 days and experienced a similar quality of life.

"The QUARTZ trial results confirmed that whole brain radiotherapy can be safely omitted without a clinically significant reduction in overall survival or quality of life. This means some patients can be spared the potential side effects of whole brain radiotherapy," said Mulvenna. Such side effects can include headaches, nausea, vomiting, fatigue, hearing loss, and memory and speech difficulty.

Mulvenna added that for patients under 60, radiotherapy may offer another three weeks of survival, but the treatment should still be weighed against the potential side effects. She also said that the study is widely accepted in the oncology sector.

"Colleagues have welcomed this data which has given them better evidence for informed conversations with patients regarding the best approach to quality and duration of life," said Mulvenna. "The uptake of whole brain radiotherapy as standard treatment has fallen significantly in the UK since our results have become public."

According to the American Cancer Society, lung cancer (both small and non-small cell) is the second most common cancer in men and women. While research has doubled overall cancer survival rates, progress has not been the same across all cancer types and survival for lung cancer remains low. In the U.S. about 225,000 new cases are diagnosed annually, with about 158,000 deaths annually.

She added that the QUARTZ study indicates that steroids and supportive care - including pain killers - are the best therapy for such lung to brain cancer patients.

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED